Beximco Pharmaceuticals Ltd.
BXP | IL
Overview
Corporate Details
- ISIN(s):
- US0885792061
- LEI:
- 213800IMBBD6TIOQGB56
- Country:
- Bangladesh
- Address:
- N/A
- Website:
- https://www.beximcopharma.com
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-13 17:10 |
Report Publication Announcement
Request of Extension to Publish Q1 Results
|
English | 11.2 KB | ||
| 2025-11-04 08:25 |
Regulatory Filings
Change of Name to Beximco Pharmaceuticals PLC.
|
English | 10.8 KB | ||
| 2025-10-27 16:53 |
Report Publication Announcement
Request of Extension to Publish Financial Results
|
English | 11.3 KB |
Automate Your Workflow. Get a real-time feed of all Beximco Pharmaceuticals Ltd. filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Beximco Pharmaceuticals Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Beximco Pharmaceuticals Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Develops advanced wound healing and infection control solutions for burns and chronic wounds.
Sweden
S2M
Sweden
S2M
Develops human polyclonal antibodies for autoimmune disorders and infectious diseases.
United States of America
SABS
United States of America
SABS
Clinical-stage biopharma developing FASN inhibitors for MASH, acne, and cancer.
United States of America
SGMT
United States of America
SGMT
Develops & manufactures drugs for eye & liver diseases, with a broad portfolio & CDMO services.
South Korea
000520
South Korea
000520
Researches & develops drugs for cardiovascular, respiratory, and gastrointestinal disorders.
South Korea
005500
South Korea
005500
A CDMO providing end-to-end development and manufacturing services for the biopharma industry.
South Korea
207940
South Korea
207940
Engineering cells as medicine to repair genes and treat cancer, diabetes, and autoimmune disorders.
United States of America
SANA
United States of America
SANA